drugset
drugset / Trial / NCT03333083

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen

NCT03333083 ↗

Phase 3 Terminated 17 enrolled Judit Pich Fundacion Clinic per a la Recerca Biomédica · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase 3b, single arm, simplification study with dual therapy including Lamivudine (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current regimen.

Timeline

Start
2018-05-03
Primary completion
2020-06-25
Completion
2020-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 300 mg —
Subject Raltegravir Other / unclassified 1200 mg —

Indications

HIV infectious disease